No Data
No Data
12 Health Care Stocks Moving In Friday's Pre-Market Session
Nanobiotix to Participate in Multiple Investor Conferences in February and March 2025
Sector Update: Health Care Stocks Rise Premarket Tuesday
Nanobiotix Doses First Patient in Phase 2 Study of Lung Cancer Therapy
Nanobiotix Begins Phase 2 Trial for Innovative Cancer Treatment in Stage 3 Lung Cancer
NANOBIOTIX Announces First Patient Dosed in a New Randomized Phase 2 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Stage 3 Unresectable Non-Small Cell Lung Cancer